Tasneem Peeraully, MD
Neurology · Summit, NJNPI 1346516515
Payments from drug & device makers
Across 39 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$170
- MDD US Operations, LLC$152
- Boston Scientific$120
- Insightec,inc$83
- Medtronic$71
- Abbott$65
- plus $166 from 9 others
What the payments were for
- Speaking & faculty fees$142%
- Food & beverage$81398%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $170 |
| MDD US Operations, LLC | 10 | $152 |
| Boston Scientific | 3 | $120 |
| Insightec,inc | 1 | $83 |
| Medtronic | 1 | $71 |
| Abbott | 1 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $44 |
| Merz North America, Inc. | 2 | $26 |
| Merz Pharmaceuticals, LLC | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| GE HealthCare | 1 | $14 |
| Acorda Therapeutics, Inc | 1 | $14 |
| UCB, Inc. | 1 | $13 |
| Zyla Life Sciences, Inc. | 1 | $13 |
| Ipsen Biopharmaceuticals, Inc | 1 | $11 |
How this compares
$827 in reported general payments places this provider in the 35th percentile of 521 neurology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 57 | $403,287 |
| RytaryCarbidopa/Levodopa | 38 | $52,118 |
| NourianzIstradefylline | 12 | $42,471 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 303 | $10,785 |
| Entacapone | 23 | $6,113 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 71 | $2,926 |
| Rasagiline Mesylate | 14 | $2,540 |
| AmantadineAmantadine Hcl | 37 | $2,155 |
| Quetiapine Fumarate | 37 | $737 |
| Propranolol Hcl | 26 | $647 |
| Gabapentin | 29 | $601 |
| Donepezil Hcl | 30 | $564 |
| Ropinirole Hcl | 13 | $343 |
| Clonazepam | 25 | $260 |
| Sertraline Hcl | 19 | $247 |
Paid to pharmacies, not to this prescriber.
Other neurology in Summit
- Marcie RabinSummit$387K
- Robert AikenSummit$131K
- Mary Ann PiconeTeaneck$2.8M
- Steven BromleyAudubon$1.7M
- David DuncanNeptune$1.5M
- Lana Zhovtis RyersonNeptune$1.3M
- Amos KatzEatontown$1.2M
- Fiona GuptaOradell$1.1M
- Andrew SylvesterBridgewater$1.1M
- Machteld HillenNewark$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.